Our Location
Midway Research Center
Midway Research Center’s primary objective is to improve the treatment options of the community by giving the community access to cutting edge treatment and the latest in pharmaceutical research. Many patients who cannot afford medications, or who are no longer responding to their medicines have gained access to necessary medical treatments that are either too expensive or not yet commercially available.
The research leaders at Midway Research Center has given more than 500 patients access to free and advanced medical treatment and an improved medication regimen that has ensured a better quality of life. By participating in these clinical trials, it is also the company’s goal to help the medical community continuously gather pertinent information about diseases. We believe that it is only through continuous education and research that we can only fully understand the disease, which will hopefully lead us to the ultimate goal – a cure.
Led by Moti Ramgopal, MD, FACP, FIDSA, and Brenda Jacobs, DNP, ARNP, AAHIVS, Midway Research Center currently completed more than 250 clinical trials, involving Phase I to Phase IV, ranging from HIV studies, to infectious diseases treatments that gave more than $5,000,000 in care to patients. These studies involved every new HIV Treatment Drug to enter the market in the past decade.
Rapid Initiation of Symtuza for HIV Treatment Shows Promise
https://www.mdmag.com/medical-
DIAMOND study: 48-week results show long-term efficacy of Symtuza
Janssen Presents New Data From First Phase 3 Trial Of Single-Tablet Regimen In Rapid Initiation Model Of Care Demonstrating Safety, Efficacy With Symtuza Through 48 Weeks
Trial Demonstrates Safety and Efficacy of HIV Combination Therapy
Infectious Disease Special Edition – Symtuza Achieves Undetectable Viral Load Through 48 Weeks
Healio – DIAMOND Study: 48-week Results Show Long-term Efficacy Of Symtuza
POZ – Rapidly Starting Symtuza After HIV Diagnosis Tied To High Viral Suppression
Contagion Live – The ID Pipeline: FDA Activity From The Week Of April 7, 2019
Endpoints News – Going Viral? J&J Tries To Spark A Twitterstorm For The Latest Data On Its HIV Med
Pharmaceutical Business Review — Janssen’s HIV Drug SYMTUZA Yields Positive Results In DIAMOND Trial
Drug Development & Technology – Janssen Reports Positive Data From Symtuza’s DIAMOND Trial
Pharmafile – Janssen’s Symtuza Around 90% Effective In Achieving Undetectable HIV-1 Viral Loads, When Used Immediately Following Diagnosis
Zacks (Picked up by Nasdaq) – Pharma Stock Roundup: J&J Presents New Data on Symtuza
Market Size Forecasters – Janssen Unveils Data From First Phase-3 Trial Of Single-tablet Regimen
MT Newswires (Picked up by Nasdaq) – Health Care Sector Update for 04/11/2019: JNJ,ICPT,INNT,SGEN
BioSpace – Janssen’s HIV Drug Symtuza Shows Long-Term Effect in Late Stage Trial
Pharmacy Times – Trial Demonstrates Safety and Efficacy of HIV Combination Therapy
MD Magazine – Rapid Initiation of Symtuza for HIV Treatment Shows Promise
Seeking Alpha – J&J’s Symtuza Shows Long-Term Effect In Late-Stage HIV Study
“Without research, we can’t discover new medicines and advanced clinical technologies or uncover new methods of detecting and treating disease. Research is critical to advancing the quality of care we offer. “
Discover The Future
We are a multi-disciplinary research facility committed to focussed and efficient drug discovery